Ostrich produce cross-reactive neutralization antibodies against pandemic influenza virus A/H1N1 following immunization with a seasonal influenza vaccine
- PMID: 22977467
- PMCID: PMC3440658
- DOI: 10.3892/etm.2010.180
Ostrich produce cross-reactive neutralization antibodies against pandemic influenza virus A/H1N1 following immunization with a seasonal influenza vaccine
Abstract
An outbreak of influenza in 2009 was found to be caused by a novel strain of influenza virus designated as pandemic influenza A/H1N1 2009. Vaccination with recent seasonal influenza vaccines induced little or no cross-reactive antibody response to the pandemic influenza virus A/H1N1 2009 in any age group in human populations. Accordingly, most people had low immunity against this pathogen, thus resulting in the worldwide spread of the infection to produce a so-called 'pandemic'. This report presents the important finding that ostrich eggs generate cross-reactive antibodies to the pandemic influenza virus A/H1N1 following immunization of female ostrich with a seasonal influenza vaccine. This simple method produced a large amount of antibodies against influenza viruses by one female ostrich. An enzyme-linked immunosorbent assay (ELISA) and immunocytochemistry indicated that the ostrich antibodies possessed strong cross-reactivity to the pandemic A/H1N1 as well as to the seasonal A/H1N1, A/H3N2 and B viruses. The hemaggregation activities of erythrocytes induced by this pandemic strain were also inhibited by the ostrich antibodies. In addition, the cytopathological effects of infection with a pandemic virus on MDCK cells were clearly inhibited in co-cultures with the ostrich antibodies, thereby indicating the neutralization of viral infectivity in the cells. In conclusion, cross-reactive neutralization antibodies against pandemic influenza virus A/H1N1 2009 were successfully generated in ostrich eggs produced by females immunized with seasonal influenza viral vaccine.
Figures

Similar articles
-
Antibodies against swine influenza virus neutralize the pandemic influenza virus A/H1N1.Mol Med Rep. 2011 Mar-Apr;4(2):209-14. doi: 10.3892/mmr.2011.410. Epub 2011 Jan 3. Mol Med Rep. 2011. PMID: 21468553
-
Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades.Influenza Other Respir Viruses. 2011 Jan;5(1):13-23. doi: 10.1111/j.1750-2659.2010.00177.x. Epub 2010 Nov 3. Influenza Other Respir Viruses. 2011. PMID: 21138536 Free PMC article.
-
Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection.Antiviral Res. 2015 Feb;114:106-12. doi: 10.1016/j.antiviral.2014.12.008. Epub 2014 Dec 13. Antiviral Res. 2015. PMID: 25513756
-
Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.N Engl J Med. 2009 Nov 12;361(20):1945-52. doi: 10.1056/NEJMoa0906453. Epub 2009 Sep 10. N Engl J Med. 2009. PMID: 19745214
-
Boosting heterosubtypic neutralization antibodies in recipients of 2009 pandemic H1N1 influenza vaccine.Clin Infect Dis. 2012 Jan 1;54(1):17-24. doi: 10.1093/cid/cir753. Epub 2011 Nov 3. Clin Infect Dis. 2012. PMID: 22052887 Free PMC article.
Cited by
-
Immunoglobulin Y for Potential Diagnostic and Therapeutic Applications in Infectious Diseases.Front Immunol. 2021 Jun 9;12:696003. doi: 10.3389/fimmu.2021.696003. eCollection 2021. Front Immunol. 2021. PMID: 34177963 Free PMC article. Review.
-
Non-conventional expression systems for the production of vaccine proteins and immunotherapeutic molecules.Hum Vaccin Immunother. 2017 Apr 3;13(4):947-961. doi: 10.1080/21645515.2016.1260795. Epub 2016 Dec 1. Hum Vaccin Immunother. 2017. PMID: 27905833 Free PMC article. Review.
-
Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies.Biomolecules. 2021 Jul 21;11(8):1072. doi: 10.3390/biom11081072. Biomolecules. 2021. PMID: 34439738 Free PMC article. Review.
References
-
- Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, Deyde V, Okomo-Adhiambo M, Gubareva L, Barnes J, Smith CB, Emery SL, Hillman MJ, Rivailler P, Smagala J, De Graaf M, Burke DF, Fouchier RA, Pappas C, Alpuche-Aranda CM, López-Gatell H, Olivera H, López I, Myers CA, Faix D, Blair PJ, Yu C, Keene KM, Dotson PD, Jr, Boxrud D, Sambol AR, Abid SH, St George K, Bannerman T, Moore AL, Stringer DJ, Blevins P, Demmler-Harrison GJ, Ginsberg M, Kriner P, Waterman S, Smole S, Guevara HF, Belongia EA, Clark PA, Beatrice ST, Donis R, Katz J, Finelli L, Bridges CB, Shaw M, Jernigan DB, Uyeki TM, Smith DJ, Klimov AI, Cox NJ. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009;325:197–201. - PMC - PubMed
-
- Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360:2605–2615. - PubMed
-
- Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, Liu F, Dong L, DeVos J, Gargiullo PM, Brammer TL, Cox NJ, Tumpey TM, Katz JM. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009;361:1945–1952. - PubMed
-
- Adachi K, Handharyani E, Sari DK, Takama K, Fukuda K, Endo I, Yamamoto R, Sawa M, Tanaka M, Konisi I, Tsukamoto Y. Development of neutralization antibodies against highly pathogenic H5N1 avian influenza virus using ostrich (Struthio camelus) yolk. Mol Med Rep. 2008;1:203–209. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources